Sinovac Biotech logo

SVA - Sinovac Biotech News Story

$6.47 0.0  0.0%

Last Trade - 22/02/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £365.8m
Position in Universe th / 7015

Turkish COVID-19 vaccine starts Phase III trials

Tue 22nd June, 2021 3:24pm
ISTANBUL, June 22 (Reuters) - Turkey on Tuesday kicked off
Phase III trials for its COVID-19 vaccine, named "Turkovac" by
President Tayyip Erdogan who said the shot should be available
for use by the end of the year.
    Ankara currently administers vaccines developed by Sinovac
 SVA.O , as well as by Pfizer  PFE.N  and Biontech  22UAy.DE .
Turkey also granted an emergency use authorization for Russia's
Sputnik V. People over 25 are eligible for the vaccine.
    "It is not clear how long this disease will go on and how
much mutation it will go through. It is critical that we have
our own vaccine against this disease," Erdogan told an event to
mark the inoculation of the first Phase III volunteer with the
vaccine, which uses an inactivated virus. 
    Turkey has sharply accelerated COVID-19 vaccinations,
delivering more than 1 million a day last week and prompting
hopes of a rebound in the economy and tourism sector.
 urn:newsml:reuters.com:*:nL2N2O10AO

 (Reporting by Ezgi Erkoyun; Editing by Dominic Evans)
 ((ezgi.erkoyun@thomsonreuters.com; +90-212-350 7051; Reuters
Messaging: ezgi.erkoyun.thomsonreuters.com@reuters.net;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.